Tarsus Pharmaceuticals (TARS) News Today $75.03 +0.83 (+1.12%) As of 02:18 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Tarsus Pharmaceuticals Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock Has Average Price Target of $100.86 According to BrokeragesOctober 30 at 2:28 AM | marketbeat.comTarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026October 29 at 4:30 PM | globenewswire.comTarsus Names Neera Clase Commercial Chief To Expand XDEMVY Reach And Lead Pipeline PlanningOctober 29 at 7:35 AM | rttnews.comTarsus Pharmaceuticals, Inc. Announces Appointment of Neera Clase as Chief Commercial Officer, Effective November 1, 2026October 28 at 3:34 PM | marketscreener.comMTarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial OfficerOctober 28 at 8:30 AM | globenewswire.comTarsus Pharmaceuticals (TARS) Set to Release Quarterly Earnings on TuesdayOctober 27 at 7:41 AM | marketbeat.comETFs Are Net Sellers of Tarsus Pharmaceuticals (TARS) on Oct. 16October 20, 2026 | finance.yahoo.comTarsus Pharmaceuticals, Inc. $TARS Holdings Lowered by Assenagon Asset Management S.A.October 18, 2026 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Stock Rating Upgraded by Zacks ResearchOctober 15, 2026 | marketbeat.comBank of America Securities Reaffirms Their Buy Rating on Tarsus Pharmaceuticals (TARS)October 14, 2026 | theglobeandmail.comTarsus Pharmaceuticals (NASDAQ:TARS) Shares Climb 3.8% - Time to Buy?October 12, 2026 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Stock Moved Down to Strong Sell by Zacks ResearchOctober 8, 2026 | marketbeat.comTarsus Pharmaceuticals: XDEMVY Now Pays The Bills, And The Retina Deals Work Like OptionsOctober 6, 2026 | seekingalpha.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock Now Rated "Moderate Buy" by Wall Street AnalystsOctober 5, 2026 | marketbeat.comTarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry ...September 29, 2026 | markets.businessinsider.comTarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual MeetingSeptember 29, 2026 | globenewswire.comTarsus Pharmaceuticals (TARS) Receives a Buy from Goldman SachsSeptember 25, 2026 | theglobeandmail.comTarsus Pharmaceuticals Insider Sold Shares Worth $979,744, According to a Recent SEC FilingSeptember 19, 2026 | finance.yahoo.comInsider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells $905,600.00 in StockSeptember 10, 2026 | insidertrades.comTarsus Pharmaceuticals Shares Rise After Closing Alkeus Pharmaceuticals AcquisitionSeptember 4, 2026 | marketscreener.comMTarsus Pharmaceuticals Closes Acquisition of Alkeus PharmaceuticalsSeptember 4, 2026 | finance.yahoo.comTarsus Pharmaceuticals Completes Alkeus Acquisition; Adds Phase 3 Stargardt Disease ProgramSeptember 4, 2026 | rttnews.comTarsus Pharmaceuticals Completes Acquisition of Alkeus, Adds Gildeuretinol for Stargardt Disease to PipelineSeptember 4, 2026 | quiverquant.comQTarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye CareSeptember 4, 2026 | globenewswire.comInsider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $339,829.86 in StockSeptember 4, 2026 | insidertrades.comAlkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt DiseaseSeptember 3, 2026 | globenewswire.comTarsus to Participate in Upcoming Investor ConferencesSeptember 1, 2026 | globenewswire.comAlkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orphan Drug Designation to Gildeuretinol for Stargardt DiseaseAugust 24, 2026 | globenewswire.comMizuho Securities Reaffirms Their Buy Rating on Tarsus Pharmaceuticals (TARS)August 15, 2026 | theglobeandmail.comOppenheimer Remains a Buy on Tarsus Pharmaceuticals (TARS)August 15, 2026 | theglobeandmail.comTarsus (TARS) Q2 2026 Earnings Call TranscriptAugust 13, 2026 | finance.yahoo.comTarsus joins Stargardt race to market with $800m Alkeus takeoverAugust 7, 2026 | finance.yahoo.comTarsus Pharmaceuticals Inc (TARS) (Q2 2026) Earnings Call Highlights: Record XDEMVY Sales and ...August 6, 2026 | finance.yahoo.comTarsus projects $685M-$705M in 2026 XDEMVY net product sales while advancing Alkeus acquisitionAugust 6, 2026 | seekingalpha.comTarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call TranscriptAugust 6, 2026 | seekingalpha.comTarsus Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call PresentationAugust 6, 2026 | seekingalpha.comTarsus Pharmaceuticals to buy Alkeus PharmaceuticalsAugust 6, 2026 | msn.comTarsus to expand eye disease pipeline with up to $800 million Alkeus acquisitionAugust 6, 2026 | msn.comTarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of GrowthAugust 6, 2026 | globenewswire.comTarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity FinancingAugust 6, 2026 | globenewswire.comTarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership PositionAugust 6, 2026 | globenewswire.comTarsus Pharmaceuticals to Host Second Quarter 2026 Financial Results Webcast and Corporate UpdateAugust 5, 2026 | quiverquant.comQTarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026August 5, 2026 | globenewswire.comTarsus Pharmaceuticals: Q2 2026 Rebound In Sales Possible, Catalysts ApproachingJuly 24, 2026 | seekingalpha.comGuggenheim Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)July 16, 2026 | theglobeandmail.comTarsus Pharmaceuticals (TARS) Replaces Its Commercial Chief While iRenix Talks ContinueJuly 15, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: UnitedHealth (UNH) and Tarsus Pharmaceuticals (TARS)July 15, 2026 | theglobeandmail.comTarsus Pharmaceuticals Announces Chief Commercial Officer TransitionJuly 13, 2026 | tipranks.comTarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of GrowthJuly 13, 2026 | globenewswire.comTarsus Pharmaceuticals, Inc. Common Stock (TARS)July 12, 2026 | nasdaq.com Tarsus Pharmaceuticals Media Mentions By Week Tarsus Pharmaceuticals Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TARS News Sentiment▼0.270.66▲Average Healthcare News Sentiment Tarsus Pharmaceuticals News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TARS Articles This Week▼75▲TARS Articles Average Week Tarsus Pharmaceuticals Trends on MarketBeatThis week vs. last weekNew Followers1Searches1Page Views1,814-11% Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Jazz Pharmaceuticals News Corcept Therapeutics News Elanco Animal Health News Dr. Reddy's Laboratories News Axsome Therapeutics News Lantheus News Amneal Pharmaceuticals News Belite Bio News Veradermics News Regencell Bioscience News News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Tarsus Pharmaceuticals dated 10/30/2026. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | SponsoredWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
